Targeting CDKN3 in cervical cancer. (October 2014)

• Record Type: Journal Article
• Authors: Berumen, Jaime; Espinosa, Ana María; Medina, Ingrid
• Is Part Of: Expert opinion on therapeutic targets. Volume 18:Number 10(2014:Oct.)
• Page Start: 1149
• Page End: 1162
• Publication Date: 2014-10
• Subjects: Drugs -- Research -- Periodicals; 615.072
• DOI: 10.1517/14728222.2014.941808
• Languages: English
• ISSNs: 1744-7631

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold> <italic>Introduction:</italic> </bold> The cyclin-dependent kinase inhibitor 3 gene (<italic>CDKN3</italic>), which is involved in mitosis, has been found upregulated and associated with low survival in cervical cancer (CC) patients. Therefore, as in other cancers, <italic>CDKN3</italic> could be a potential target in CC.</p> <p> <bold> <italic>Areas covered:</italic> </bold> In this review, the authors analyzed the evidence supporting the upregulation of <italic>CDKN3</italic> in CC, its role in mitosis and the cell cycle, the evidence that <italic>CDKN3</italic> may be useful as marker for survival and selection of CC patients for additional chemotherapy or specific target cancer therapy, the data supporting the role of <italic>CDKN3</italic> in cell proliferation, and how <italic>CDKN3</italic> targeting with specific small interfering RNA (siRNAs) suppress cell proliferation of cell lines derived from CC and other cancers. Finally, we discuss if the upregulation of <italic>CDKN3</italic> can be part of the human papilloma virus strategy to avoid the mitosis checkpoint, the research to find small specific drugs to target <italic>CDKN3</italic> and the advantages that <italic>CDKN3</italic> has as target for novel drug design for CC treatment.</p> <p> <bold> <italic>Expert opinion:</italic> </bold> <italic>CDKN3</italic> might be useful not only as marker for survival and selection of CC patients for additional chemotherapy or specific target cancer therapy, but also as a potential target to develop specific small drugs to combat CC.</p> </abstract>